{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T20:48:12Z","timestamp":1761598092229,"version":"3.37.3"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,7,4]],"date-time":"2019-07-04T00:00:00Z","timestamp":1562198400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,7,4]],"date-time":"2019-07-04T00:00:00Z","timestamp":1562198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["KFO210"],"award-info":[{"award-number":["KFO210"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005677","name":"Jos\u00e9 Carreras Leuk\u00e4mie-Stiftung","doi-asserted-by":"publisher","award":["AH06-01"],"award-info":[{"award-number":["AH06-01"]}],"id":[{"id":"10.13039\/501100005677","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s00432-019-02961-9","type":"journal-article","created":{"date-parts":[[2019,7,4]],"date-time":"2019-07-04T14:42:00Z","timestamp":1562251320000},"page":"2149-2156","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Low number of intrafollicular T cells may predict favourable response to rituximab-based immuno-chemotherapy in advanced follicular lymphoma: a secondary analysis of a randomized clinical trial"],"prefix":"10.1007","volume":"145","author":[{"given":"Laura","family":"Budau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Wilhelm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland","family":"Moll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f6rg","family":"J\u00e4kel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carsten","family":"Hirt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gottfried","family":"D\u00f6lken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Maschmeyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen","family":"Neubauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantin","family":"Strauch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Burchert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Herold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7606-8760","authenticated-orcid":false,"given":"Andreas","family":"Neubauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,7,4]]},"reference":[{"key":"2961_CR1","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/bjh.14201","volume":"175","author":"YN Blaker","year":"2016","unstructured":"Blaker YN, Spetalen S, Brodtkorb M et al (2016) The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era. Br J Haematol 175:102\u2013114. \n                              https:\/\/doi.org\/10.1111\/bjh.14201","journal-title":"Br J Haematol"},{"key":"2961_CR2","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1200\/JCO.2007.12.8298","volume":"26","author":"D Canioni","year":"2008","unstructured":"Canioni D, Salles G, Mounier N et al (2008) High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. J Clin Oncol 26:440\u2013446. \n                              https:\/\/doi.org\/10.1200\/jco.2007.12.8298","journal-title":"J Clin Oncol"},{"key":"2961_CR3","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1111\/j.1365-2141.2009.07651.x","volume":"145","author":"A Carbone","year":"2009","unstructured":"Carbone A, Gloghini A, Cabras A, Elia G (2009) The Germinal centre-derived lymphomas seen through their cellular microenvironment. Br J Haematol 145:468\u2013480. \n                              https:\/\/doi.org\/10.1111\/j.1365-2141.2009.07651.x","journal-title":"Br J Haematol"},{"key":"2961_CR4","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1056\/NEJMoa041869","volume":"351","author":"SS Dave","year":"2004","unstructured":"Dave SS, Wright G, Tan B et al (2004) Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 351:2159\u20132169","journal-title":"N Engl J Med"},{"key":"2961_CR5","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1158\/2326-6066.CIR-13-0158","volume":"2","author":"J Du","year":"2014","unstructured":"Du J, Lopez-Verges S, Pitcher BN et al (2014) CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells. Cancer Immunol Res 2:878\u2013889. \n                              https:\/\/doi.org\/10.1158\/2326-6066.cir-13-0158","journal-title":"Cancer Immunol Res"},{"key":"2961_CR6","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.exphem.2006.02.015","volume":"34","author":"L Fischer","year":"2006","unstructured":"Fischer L, Penack O, Gentilini C, Nogai A, Muessig A, Thiel E, Uharek L (2006) The anti-lymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cells. Exp Hematol 34:753\u2013759. \n                              https:\/\/doi.org\/10.1016\/j.exphem.2006.02.015","journal-title":"Exp Hematol"},{"key":"2961_CR7","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1200\/JCO.2006.06.1648","volume":"25","author":"AM Glas","year":"2007","unstructured":"Glas AM, Knoops L, Delahaye L et al (2007) Gene-expression and immunohistochemical study of specific T cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. J Clin Oncol 25:390\u2013398","journal-title":"J Clin Oncol"},{"key":"2961_CR8","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/j.1365-2141.2006.06255.x","volume":"135","author":"A Harjunpaa","year":"2006","unstructured":"Harjunpaa A, Taskinen M, Nykter M et al (2006) Differential gene expression in non-malignant tumour microenvironment is associated with outcome in follicular lymphoma patients treated with rituximab and CHOP. Br J Haematol 135:33\u201342. \n                              https:\/\/doi.org\/10.1111\/j.1365-2141.2006.06255.x","journal-title":"Br J Haematol"},{"key":"2961_CR9","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1200\/JCO.2006.06.4618","volume":"25","author":"M Herold","year":"2007","unstructured":"Herold M, Haas A, Srock S et al (2007) Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 25:1986\u20131992","journal-title":"J Clin Oncol"},{"key":"2961_CR10","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1007\/s00432-015-1963-9","volume":"141","author":"M Herold","year":"2015","unstructured":"Herold M, Scholz CW, Rothmann F, Hirt C, Lakner V, Naumann R (2015) Long-term follow-up of rituximab plus first-line mitoxantrone, chlorambucil, prednisolone and interferon-alpha as maintenance therapy in follicular lymphoma. J Cancer Res Clin Oncol 141:1689\u20131695. \n                              https:\/\/doi.org\/10.1007\/s00432-015-1963-9","journal-title":"J Cancer Res Clin Oncol"},{"key":"2961_CR11","doi-asserted-by":"publisher","first-page":"3809","DOI":"10.1182\/blood-2008-10-185280","volume":"113","author":"SP Hilchey","year":"2009","unstructured":"Hilchey SP, Hyrien O, Mosmann TR et al (2009) Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a \u201cvaccinal effect\u201d of rituximab. Blood 113:3809\u20133812. \n                              https:\/\/doi.org\/10.1182\/blood-2008-10-185280","journal-title":"Blood"},{"key":"2961_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(18)30102-5","author":"S Huet","year":"2018","unstructured":"Huet S, Tesson B, Jais JP et al (2018) A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts. Lancet Oncol. \n                              https:\/\/doi.org\/10.1016\/s1470-2045(18)30102-5","journal-title":"Lancet Oncol"},{"key":"2961_CR13","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s00277-017-3218-0","volume":"97","author":"A Janikova","year":"2018","unstructured":"Janikova A, Bortlicek Z, Campr V et al (2018) The incidence of biopsy-proven transformation in follicular lymphoma in the rituximab era. A retrospective analysis from the Czech Lymphoma Study Group (CLSG) database. Ann Hematol 97:669\u2013678. \n                              https:\/\/doi.org\/10.1007\/s00277-017-3218-0","journal-title":"Ann Hematol"},{"key":"2961_CR14","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s00277-017-3175-7","volume":"97","author":"Y Kusano","year":"2018","unstructured":"Kusano Y, Yokoyama M, Inoue N et al (2018) Delayed recovery of serum immunoglobulin G is a poor prognostic marker in patients with follicular lymphoma treated with rituximab maintenance. Ann Hematol 97:289\u2013297. \n                              https:\/\/doi.org\/10.1007\/s00277-017-3175-7","journal-title":"Ann Hematol"},{"key":"2961_CR15","doi-asserted-by":"publisher","first-page":"5371","DOI":"10.1182\/blood-2011-04-345777","volume":"118","author":"C Laurent","year":"2011","unstructured":"Laurent C, Muller S, Do C et al (2011) Distribution, function, and prognostic value of cytotoxic T lymphocytes in follicular lymphoma: a 3-D tissue-imaging study. Blood 118:5371\u20135379. \n                              https:\/\/doi.org\/10.1182\/blood-2011-04-345777","journal-title":"Blood"},{"key":"2961_CR16","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s00277-014-2173-2","volume":"94","author":"YJ Li","year":"2015","unstructured":"Li YJ, Li ZM, Xia ZJ et al (2015) High APRIL but not BAFF serum levels are associated with poor outcome in patients with follicular lymphoma. Ann Hematol 94:79\u201388. \n                              https:\/\/doi.org\/10.1007\/s00277-014-2173-2","journal-title":"Ann Hematol"},{"key":"2961_CR17","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.2085","author":"S Liu","year":"2017","unstructured":"Liu S, Chen B, Burugu S et al (2017) Role of cytotoxic tumor-infiltrating lymphocytes in predicting outcomes in metastatic her2-positive breast cancer: a secondary analysis of a randomized clinical trial. JAMA Oncol. \n                              https:\/\/doi.org\/10.1001\/jamaoncol.2017.2085","journal-title":"JAMA Oncol"},{"key":"2961_CR18","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","volume":"105","author":"R Marcus","year":"2005","unstructured":"Marcus R, Imrie K, Belch A et al (2005) CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105:1417\u20131423","journal-title":"Blood"},{"key":"2961_CR19","doi-asserted-by":"publisher","first-page":"4579","DOI":"10.1200\/JCO.2007.13.5376","volume":"26","author":"R Marcus","year":"2008","unstructured":"Marcus R, Imrie K, Solal-Celigny P et al (2008) Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 26:4579\u20134586","journal-title":"J Clin Oncol"},{"key":"2961_CR20","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","volume":"16","author":"A Pastore","year":"2015","unstructured":"Pastore A, Jurinovic V, Kridel R et al (2015) Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol 16:1111\u20131122. \n                              https:\/\/doi.org\/10.1016\/s1470-2045(15)00169-2","journal-title":"Lancet Oncol"},{"key":"2961_CR21","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1001\/jamaoncol.2015.3239","volume":"2","author":"EA Perez","year":"2016","unstructured":"Perez EA, Ballman KV, Tenner KS, Thompson EA, Badve SS, Bailey H, Baehner FL (2016) Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer. JAMA Oncolo 2:56\u201364. \n                              https:\/\/doi.org\/10.1001\/jamaoncol.2015.3239","journal-title":"JAMA Oncolo"},{"key":"2961_CR22","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/S1470-2045(16)30097-3","volume":"17","author":"LH Sehn","year":"2016","unstructured":"Sehn LH, Chua N, Mayer J et al (2016) Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol 17:1081\u20131093. \n                              https:\/\/doi.org\/10.1016\/s1470-2045(16)30097-3","journal-title":"Lancet Oncol"},{"key":"2961_CR23","doi-asserted-by":"publisher","first-page":"5784","DOI":"10.1158\/1078-0432.CCR-07-0778","volume":"13","author":"M Taskinen","year":"2007","unstructured":"Taskinen M, Karjalainen-Lindsberg ML, Nyman H, Eerola LM, Leppa S (2007) A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone. Clin Cancer Res 13:5784\u20135789. \n                              https:\/\/doi.org\/10.1158\/1078-0432.ccr-07-0778","journal-title":"Clin Cancer Res"},{"key":"2961_CR24","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1158\/1078-0432.CCR-09-2487","volume":"16","author":"BE Wahlin","year":"2010","unstructured":"Wahlin BE, Aggarwal M, Montes-Moreno S et al (2010) A unifying microenvironment model in follicular lymphoma: outcome is predicted by programmed death-1\u2013positive, regulatory, cytotoxic, and helper T cells and macrophages. Clin Cancer Res 16:637\u2013650. \n                              https:\/\/doi.org\/10.1158\/1078-0432.ccr-09-2487","journal-title":"Clin Cancer Res"},{"key":"2961_CR25","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1053\/j.seminhematol.2010.01.011","volume":"47","author":"GJ Weiner","year":"2010","unstructured":"Weiner GJ (2010) Rituximab: mechanism of action. Semin Hematol 47:115\u2013123. \n                              https:\/\/doi.org\/10.1053\/j.seminhematol.2010.01.011","journal-title":"Semin Hematol"},{"key":"2961_CR26","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.humpath.2017.03.023","volume":"64","author":"L Xerri","year":"2017","unstructured":"Xerri L, Huet S, Venstrom JM et al (2017) Rituximab treatment circumvents the prognostic impact of tumor-infiltrating T cells in follicular lymphoma patients. Hum Pathol 64:128\u2013136. \n                              https:\/\/doi.org\/10.1016\/j.humpath.2017.03.023","journal-title":"Hum Pathol"},{"key":"2961_CR27","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1007\/s00277-016-2800-1","volume":"95","author":"S Yuda","year":"2016","unstructured":"Yuda S, Maruyama D, Maeshima AM et al (2016) Influence of the watch and wait strategy on clinical outcomes of patients with follicular lymphoma in the rituximab era. Ann Hematol 95:2017\u20132022. \n                              https:\/\/doi.org\/10.1007\/s00277-016-2800-1","journal-title":"Ann Hematol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-019-02961-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-019-02961-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-019-02961-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T23:13:42Z","timestamp":1593731622000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-019-02961-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,4]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["2961"],"URL":"https:\/\/doi.org\/10.1007\/s00432-019-02961-9","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"type":"print","value":"0171-5216"},{"type":"electronic","value":"1432-1335"}],"subject":[],"published":{"date-parts":[[2019,7,4]]},"assertion":[{"value":"31 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Georg Maschmeyer reports personal fees from Celgene, personal fees from Novartis, personal fees from Bristol-Myers Squibb, personal fees from Janssen-Cilag, not related to the current paper. Andreas Neubauer has received honoraria from Medupdate GmbH, not related to the current paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}